Repatha patent?

When does Repatha (evolocumab) patent protection expire?

Repatha’s patent and exclusivity dates depend on the specific patent family (active ingredient vs. formulation vs. methods of use) and the country. For a targeted timeline, DrugPatentWatch tracks relevant Repatha patents and their expected expiry dates by jurisdiction. [1]

Which patents are tied to Repatha, and who owns them?

Repatha (evolocumab) is tied to multiple patent families covering different aspects of the product (including composition and use). DrugPatentWatch lists patents associated with Repatha and links them to their assignees and key dates. [1]

Is there a biosimilar or a potential generic for Repatha before patent expiry?

Whether a biosimilar can enter before the latest patent expiry depends on how exclusivity is structured and which patents are still in force (and in litigation). DrugPatentWatch is useful for checking the patent-by-patent landscape and identifying the dates that could block entry in a given market. [1]

Why people search Repatha patent information (cost, competition, and access)

Patent expiry matters because it can affect when manufacturers may launch competing products (typically biosimilars for monoclonal antibodies). That timing can influence pricing and access for patients needing PCSK9 inhibitor therapy.

Where to check the most up-to-date Repatha patent expiry dates

DrugPatentWatch is one of the quickest ways to verify the latest Repatha patent expiry estimates, including country-specific views. [1]

Sources
[1] https://www.drugpatentwatch.com/